Ropinirole in Treatment-Resistant Depression: A 16-Week Pilot Study
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Objective: The study aimed to assess the antidepressant efficacy and tolerability of adjunctive ropinirole in outpatients with treatment-resistant depression (TRD). Method: The study sample consisted of patients with a major depressive episode (diagnosed according to DSM-IV criteria) and TRD. Ropinirole 0.25 to 1.5 mg daily was added to tricyclic antidepressants or selective serotonin reuptake inhibitors. We conducted assessments at baseline and at weeks 2, 4, 8, 12, and 16. We defined response as a 50% or greater reduction of the Montgomery–Asberg Depression Rating Scale (MADRS) total score plus a score of 1 (“very much improved”) or 2 (“much improved”) on the Clinical Global Impression of Improvement scale at endpoint. Tolerability was monitored with the Dosage Record Treatment Emergent Symptom Scale. Results: Seven patients had major depressive disorder, and 3 had bipolar II disorder. The mean maximum dose of ropinirole was 1.33 mg daily. Mean (SD) scores on the MADRS decreased from 29.6 (7.6) at baseline to 16.9 (12.1) at endpoint ( P < 0.02). At endpoint, 4 of 10 (40%) patients were responders. Two patients discontinued ropinirole because of dizziness. Conclusions: These pilot data suggest that, in selected cases of TRD, ropinirole augmentation of antidepressants is effective and relatively well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ropinirole augmentation of antidepressant treatment in a small sample of refractory patients reduced depression scores by half in 40% of patients”
From Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications (2013) · cites this paper as Cassano et al., 2005
Citations
Cites
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Self-citationGoldberg, J. F., Burdick, K. E., & Endick, C. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.564 · Cited by 372
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study
Zarate, C. A., Payne, J. L., Singh, J., Quiroz, J. A., Luckenbaugh, D. A., Denicoff, K. D., Charney, D. S., & Manji, H. K. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.03.013 · Cited by 347
The mesolimbic dopamine system as a target for rapid antidepressant action
Willner, P. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199707003-00002 · Cited by 208
Clinical Pharmacokinetics of Ropinirole
Kaye, C. M., & Nicholls, B. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039040-00001 · Cited by 175
Pérez, V. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.4.375 · Cited by 154
Sporn, J., Ghaemi, S. N., Sambur, M. R., Rankin, M. A., Recht, J., Sachs, G. S., Rosenbaum, J. F., & Fava, M. (2000) · Annals of Clinical Psychiatry · doi:10.1023/a:1009060800999 · Cited by 153
Pramipexole in treatment‐resistant depression: a 16‐week naturalistic study
Lattanzi, L., Dell'Osso, L., Cassano, P., Pini, S., Rucci, P., Houck, P. R., Gemignani, A., Battistini, G., Bassi, A., Abelli, M., et al. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01171.x · Cited by 150
Self-citationEfficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression
Maes, M. H. J., Vandoolaeghe, E., & Desnyder, R. (1996) · Journal of Affective Disorders · doi:10.1016/s0165-0327(96)00089-4 · Cited by 125
Adjunctive Dopamine Agonists in Treatment-Resistant Bipolar II Depression: an Open Case Series
Perugi, G., Toni, C., Ruffolo, G., Frare, F., & Akiskal, H. (2001) · Pharmacopsychiatry · doi:10.1055/s-2001-15872 · Cited by 108
Research works printed but not linked: 2
- 10.3109/10401230009147102 · doi:10.3109/10401230009147102 · Paper page
- Brooks DJ, 1998, Clin Neuropharmacol, 21, 101
Cited by
Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579
“Finally, DA agonists such as bromocriptine, ropinirole and pramipexole also exhibit antidepressant properties (Cassano et al., 2005; Corrigan et al., 2000; Sitland-Marken et al., 1990)).”
BackgroundInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Nutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366
“Furthermore, data from clinical studies have shown that DA agonists, such as bromocriptine, pramipexole and ropinirole, exhibit antidepressant properties (Sitland-Marken et al., 1990; Corrigan et al., 2000; Cassano et al., 2005).”
BackgroundTherapeutic Options for Treatment-Resistant Depression
Shelton, R. C., Osuntokun, O., Heinloth, A. N., & Corya, S. A. (2010) · CNS Drugs · doi:10.2165/11530280-000000000-00000 · Cited by 205
Dopamine D2-Like Receptors and the Antidepressant Response
Gershon, A. A., Vishne, T., & Grunhaus, L. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.031 · Cited by 158
Association of the COMT val158met Variant with Antidepressant Treatment Response in Major Depression
Baune, B. T., Hohoff, C., Berger, K., Neumann, A., Mortensen, S., Roehrs, T., Deckert, J., Arolt, V., & Domschke, K. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301462 · Cited by 154
Pramipexole in Psychiatry: A Systematic Review of the Literature
Aiken, C. B. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0810 · Cited by 129
Peciña, M., Sikora, M., Avery, E. T., Heffernan, J., Peciña, S., Mickey, B. J., & Zubieta, J.-K. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.427 · Cited by 115
Prins, J., Olivier, B., & Korte, S. M. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.594039 · Cited by 97
Collo, G., Cavalleri, L., Bono, F., Mora, C., Fedele, S., Invernizzi, R. W., Gennarelli, M., Piovani, G., Kunath, T., Millan, M. J., et al. (2018) · Neural Plasticity · doi:10.1155/2018/4196961 · Cited by 114
Therapeutic options in treatment-resistant depression
Vieta, E., & Colom, F. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.583675 · Cited by 102
Treatment strategies to improve and sustain remission in major depressive disorder
Madhukar H., T., & Ella J., D. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/mhtrivedi · Cited by 75
Pharmacologic approaches to treatment resistant depression: Evidences and personal experience
Tundo, A., Filippis, R. D., & Proietti, L. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i3.330 · Cited by 91
Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson???s Disease
Gallagher, D. A., & Schrag, A. E. (2008) · CNS Drugs · doi:10.2165/00023210-200822070-00003 · Cited by 104
Pae, C., Forbes, A., & Patkar, A. A. (2010) · CNS Drugs · doi:10.2165/11538980-000000000-00000 · Cited by 99
Caldiroli, A., Capuzzi, E., Tagliabue, I., Capellazzi, M., Marcatili, M., Mucci, F., Colmegna, F., Clerici, M., Buoli, M., & Dakanalis, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313070 · Cited by 70
Effects of Ropinirole on Nonmotor Symptoms of Parkinson Disease: A Prospective Multicenter Study
Rektorová, I., Baláž, M., Svátová, J., Zárubová, K., Honig, I., Dostal, V., Sedláčková, S., Nestrašil, I., Mastík, J., Bareš, M., et al. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31815d25ce · Cited by 84
Emerging targets for antidepressant therapies
Rakofsky, J. J., Holtzheimer, P. E., & Nemeroff, C. B. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.617 · Cited by 72
Dopamine agonist‐responsive depression
Hori, H., & Kunugi, H. (2013) · Psychogeriatrics · doi:10.1111/psyg.12014 · Cited by 57
Hori, H., & Kunugi, H. (2012) · The Scientific World Journal · doi:10.1100/2012/372474 · Cited by 62
“This study was also supported by Grant-in-Aid for Young Scientists (Start-up) from the JSPS (H. Hori).”
BackgroundInfluentialBeneš, H., Mattern, W., Peglau, I., Dreykluft, T., Bergmann, L., Hansen, C., Kohnen, R., Banik, N., Schoen, S., & Hornyak, M. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5879-7 · Cited by 61
Dhir, A., & Kulkarni, S. K. (2007) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2007.05.004 · Cited by 51
Kitamura, Y., Yagi, T., Kitagawa, K., Shinomiya, K., Kawasaki, H., Asanuma, M., & Gomita, Y. (2010) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-010-0521-x · Cited by 48
Integrating the monoamine and cytokine hypotheses of depression: Is histamine the missing link?
Hersey, M., Hashemi, P., & Reagan, L. P. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15392 · Cited by 46
Antidepressant drug development: Focus on triple monoamine reuptake inhibition
Lane, R. M. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114553252 · Cited by 44
Novel targets for antidepressant therapies
Holtzheimer, P. E., & Nemeroff, C. B. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0075-5 · Cited by 37
Emerging drugs for major depressive disorder
Kennedy, S. H., & Rizvi, S. J. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903107751 · Cited by 39
Recent advances in dopamine D 2 receptor ligands in the treatment of neuropsychiatric disorders
Jůza, R., Musílek, K., Mezeiová, E., Soukup, O., & Korábečný, J. (2022) · Medicinal Research Reviews · doi:10.1002/med.21923 · Cited by 37
Effects of terguride, ropinirole, and acetyl-l-carnitine on methamphetamine withdrawal in the rat
Hoefer, M. E., Voskanian, S. J., Koob, G. F., & Pulvirenti, L. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.02.023 · Cited by 37
Kitagawa, K., Kitamura, Y., Miyazaki, T., Miyaoka, J., Kawasaki, H., Asanuma, M., Sendo, T., & Gomita, Y. (2009) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-009-0405-0 · Cited by 36
Pramipexole for stage 2 treatment-resistant major depression: An open study
Inoue, T., Kitaichi, Y., Masui, T., Nakagawa, S., Boku, S., Tanaka, T., Suzuki, K., Nakato, Y., Usui, R., & Koyama, T. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.035 · Cited by 34
Advances in the Management of Treatment-Resistant Depression
Holtzheimer, P. E. (2010) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.8.4.foc488 · Cited by 29
The Use of Dopaminergic and Stimulant Drugs for the Treatment of Depression
Howland, R. H. (2012) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20120112-03 · Cited by 29
Olubodun-Obadun, T. G., Ishola, I. O., Adesokan, T. P., Anih, B. O., & Adeyemi, O. O. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116142 · Cited by 23
l-DOPA modifies the antidepressant-like effects of reboxetine and fluoxetine in rats
Miguélez, C., Berrocoso, E., Micó, J. A., & Ugedo, L. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.016 · Cited by 23
Psychosis Related to Ropinirole
Perea, E., Robbins, B. V., & Hutto, B. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.547 · Cited by 18
Stoner, S. C., Dahmen, M. M., Makos, M., Lea, J. W., Carver, L. J., & Rasu, R. S. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m183 · Cited by 18
Plausible Role of Stem Cell Types for Treating and Understanding the Pathophysiology of Depression
Sachdeva, P., Ji, S., Ghosh, S., Ghosh, S., Raghunath, M., Kim, H., Bhaskar, R., Sinha, J. K., & Han, S. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030814 · Cited by 17
Rational Antidepressant Selection: Applying Evidence-Based Medicine to Complex Real-World Patients
Bauer, M. S., Rush, A. J., Wisniewski, S. R., PhD, Kogan, J. N., PhD, Marangell, L. B., MD, Thase, M. E., MD, et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4156 · Cited by 17
Sleepiness and Depression in Parkinson’s Disease Patients Treated with Ropinirole and Levodopa
Kang, S. Y., Ryu, H., Sunwoo, M.-K., Kim, S. J., Baik, J.-S., Park, M.-Y., Park, H.-E., Kim, J., Kwon, K., Koh, S., et al. (2017) · Journal of Movement Disorders · doi:10.14802/jmd.17048 · Cited by 15
Current and Emerging Therapies for the Management of Bipolar Disorders
El‐Mallakh, R. S., Elmaadawi, A. Z., Gao, Y., Lohano, K., & Roberts, R. J. (2011) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s4441 · Cited by 15
Therapeutic Armamentarium for Treating Depression
Howland, R. H. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.07.2176 · Cited by 15
Depression in Parkinson Disease: Current Understanding and Treatment
Chen, P., & Cheng, S.-J. (2008) · International journal of gerontology · doi:10.1016/s1873-9598(09)70006-7 · Cited by 15
Ghorpade, S., Tripathi, R. K., Sonawane, D., & Manjrekar, N. A. (2011) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp.2011.027 · Cited by 13
Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder
Kaur, M., & Sanches, M. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s259302 · Cited by 12
Ropinirole Augmentation for Depression: A Randomized Controlled Trial Pilot Study
Gershon, A. A., Amiaz, R., David, H. S., & Grunhaus, L. J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000984 · Cited by 11
Panic Attack-Like Episodes Possibly Associated With Ropinirole
Alonso‐Navarro, H., Jiménez‐Jiménez, F. J., Pilo‐de‐la‐Fuente, B., & Plaza‐Nieto, J. F. (2009) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000265980.03198.55 · Cited by 8
Felger, J. C. (2023) · Advances in neurobiology · doi:10.1007/978-3-031-21054-9_16 · Cited by 6
Onoue, Y., Kuwatsuka, K., Miyazaki, I., Asanuma, M., Kitamura, Y., & Sendo, T. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00749 · Cited by 6
Polypharmazie in der Behandlung depressiver Störungen
Schmauß, M., & Messer, T. (2009) · Springer eBooks · doi:10.1007/978-3-211-79826-3_1 · Cited by 5
Pae, C., Marks, D. M., Han, C., & Patkar, A. A. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.02.011 · Cited by 5
Depressione resistente al trattamento: stato dell’arte Parte II. Trattamento
Luchini, F., Cosentino, L., Pensabene, L., Mauri, M., & Lattanzi, L. (2014) · Rivista di psichiatria · doi:10.1708/1766.19120 · Cited by 4
Self-citationRopinirole augmentation therapy in a case with treatment-resistant unipolar depression
Mihara, K., Nakamura, A. M., Kuba, T., Yakushi, T., Hotta, H., Kojima, M., & Kondo, T. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.02.022 · Cited by 4
Emerging drugs for bipolar depression: an update
Keedwell, P. A., & Young, A. H. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.872628 · Cited by 3
Ropinirole in Bipolar Disorder: Rate of Manic Switching and Change in Disease Severity
Capote, H. A., Rainka, M. M., Westphal, E. S., Beecher, J., & Gengo, F. M. (2017) · Perspectives In Psychiatric Care · doi:10.1111/ppc.12205 · Cited by 3
A Case of Ropinirole-Induced Psychosis
Grover, S., & Ghosh, A. (2010) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.10l00987gre · Cited by 2
Neuroprotection in Bipolar Depression
Aiken, C. (2010) · Springer eBooks · doi:10.1007/978-90-481-8553-5_15 · Cited by 2
McHugh, P. (2010) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/187569210792246272 · Cited by 2
10.5 The Role of Dopamine in the Pathophysiology and Treatment of Major Depressive Disorder
Dunlop, B. W., & Nemeroff, C. B. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195373035.003.0040 · Cited by 2
Treadway, M. T. (2012) · Cited by 3
Augmentation Strategies for Treatment-Resistant Disorders
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as09 · Cited by 1
Chapter 9. Augmentation Strategies for Treatment-Resistant Disorders
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd09 · Cited by 1
Chapter 3. Treatment Resistant Depression in Adolescents
Ghaziuddin, N., Barbosa, V. F., & King, C. A. (2011) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378197.lg03 · Cited by 1
Mattsson, C. M. (2013) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Was tun, wenn die antidepressive Behandlung versagt?
Schmauß, M. (2012) · NeuroTransmitter · doi:10.1007/s15016-012-0084-9
Behandlung depressiver Störungen
Schmauß, M., & Messer, T. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1849-8_1
Neural responses to reward and aversion as a possible biomarker for depression
Rzepa, E. (2017) · CentAUR (University of Reading)
Os Agonistas Dopaminérgicos e a Qualidade de Vida na Doença de Parkinson
Tumas, V. (2019) · Revista Neurociências · doi:10.34024/rnc.2006.v14.8763
Kääriäinen, T. M. (2008) · UEF eRepo (University of Eastern Finland)
P146 マイクロバブルの光散乱特性(ポスター・セッション)
土居, 七., & 岩崎, 杉. (2012) · 大会講演予講集
Current awareness in human psychopharmacology
(2006) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.732
Augmentation Strategies for Treatment-Resistant Disorders
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as09
Sun, X.-Z., Cai, Y.-X., Cai, Q.-J., Ling, X.-Y., Zhang, G.-M., Lin, J.-J., Liu, Y.-X., Shi, X., Wang, T.-Z., Wu, B., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121884
ใจสุภา, ณ., & เมืองไพศาล, ว. (2018) · Royal Thai Army Medical Journal
Metadata
- Authors
- Cassano, P., Lattanzi, L., Fava, M., Navari, S., Battistini, G., Abelli, M., & Cassano, G. B.
- Affiliations
- Massachusetts General Hospital (US)
- University of Pisa (IT)
- Director, Depression Clinical and Research Program Massachusetts General Hospital, Boston, Massachusetts
- Corresponding author
- Cassano, Paolo
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2005-05
- Volume
- 50
- Issue
- 6
- Pages
- 357-360
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- OpenAlex
- W2119768046
- Cited by
- 73
- References
- 17
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 3 · 2019: 3 · 2018: 2 · 2017: 4 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 6
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- The Canadian Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ropinirole, treatment-resistant depression, adjunctive therapy, dopamine agonists, antidepressant augmentation, major depressive disorder, bipolar II disorder, tricyclic antidepressants, selective serotonin reuptake inhibitors, tolerability, dizziness
- MeSH terms
- Adolescent, Adult, Aged, Major Depressive Disorder, Drug Resistance, Female, Humans, Indoles, Male, Middle Aged, Pilot Projects, Severity of Illness Index, Dopamine Agonists, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.